Ultimovacs Dirección

Dirección controles de criterios 3/4

El CEO de Ultimovacs es Carlos de Sousa , nombrado en Jun 2020, tiene una permanencia de 4.42 años. compensación anual total es NOK6.50M, compuesta por 74.5% salario y 25.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.076% de las acciones de la empresa, por valor de NOK56.28K. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 9.8 años, respectivamente.

Información clave

Carlos de Sousa

Chief Executive Officer (CEO)

NOK 6.5m

Compensación total

Porcentaje del salario del CEO	74.5%
Permanencia del CEO	4.4yrs
Participación del CEO	0.08%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	9.8yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Carlos de Sousa en comparación con los beneficios de Ultimovacs?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-NOK 149m
Jun 30 2024	n/a	n/a	-NOK 179m
Mar 31 2024	n/a	n/a	-NOK 178m
Dec 31 2023	NOK 7m	NOK 5m	-NOK 189m
Sep 30 2023	n/a	n/a	-NOK 204m
Jun 30 2023	n/a	n/a	-NOK 186m
Mar 31 2023	n/a	n/a	-NOK 165m
Dec 31 2022	NOK 8m	NOK 5m	-NOK 168m
Sep 30 2022	n/a	n/a	-NOK 148m
Jun 30 2022	n/a	n/a	-NOK 153m
Mar 31 2022	n/a	n/a	-NOK 168m
Dec 31 2021	n/a	n/a	-NOK 165m
Sep 30 2021	n/a	n/a	-NOK 138m
Jun 30 2021	n/a	n/a	-NOK 126m
Mar 31 2021	n/a	n/a	-NOK 124m
Dec 31 2020	NOK 5m	NOK 3m	-NOK 121m

Compensación vs. Mercado: La compensación total de Carlos($USD587.17K) está por encima de la media de empresas de tamaño similar en el mercado Norwegian ($USD300.00K).

Compensación vs. Ingresos: La compensación de Carlos ha sido consistente con los resultados de la empresa en el último año.

CEO

Carlos de Sousa (66 yo)

4.4yrs

Permanencia

NOK 6,504,000

Compensación

Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Carlos de Sousa	Chief Executive Officer	4.4yrs	NOK 6.50m	0.076% NOK 56.3k
Hans Eid	Chief Financial Officer	9yrs	NOK 4.41m	0.17% NOK 123.6k
Ingunn Westgaard	Head of Research	no data	NOK 2.57m	sin datos
Audun Tornes	Chief Technology Officer	3.8yrs	NOK 2.92m	sin datos
Jens Egil Bjorheim	Chief Medical Officer	8.4yrs	NOK 4.29m	sin datos
Oivind Foss	Head of Clinical Operations	7.3yrs	NOK 2.71m	sin datos
Orla Mc Callion	Head of Regulatory Affairs & QA	3.1yrs	NOK 2.37m	sin datos
Torill Trones	Head of Office	no data	sin datos	sin datos

5.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ULTI es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonas Einarsson	Independent Chairman	13.8yrs	NOK 450.00k	0.015% NOK 11.4k
Kari Gronas	Independent Director	5.8yrs	NOK 250.00k	0.019% NOK 14.3k
Henrik Schussler	Director	9.8yrs	NOK 250.00k	sin datos

9.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de ULTI se considera experimentada (9.8 años de antigüedad promedio).

Ultimovacs Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Recent updates

Ultimovacs ASA Announces Publication of Phase II FOCUS Trial Results on MedRxiv

New major risk - Market cap size

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Ultimovacs ASA Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Asa Announces Poster Presentation of Nipu Phase II Trial Update At Upcoming ESMO Congress 2024

Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Price target decreased by 8.6% to kr155

New minor risk - Market cap size

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

New minor risk - Share price stability

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

New minor risk - Share price stability

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New minor risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Chief Executive Officer recently bought kr145k worth of stock

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Chief Executive Officer recently bought kr134k worth of stock

Price target increased to kr151

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

Price target increased to kr151

No independent directors

Ultimovacs ASA Approves Board and Committee Changes

Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Chief Executive Officer recently bought kr94k worth of stock

Ultimovacs ASA Completes Treatment of the Second Dose Cohort in the Phase I TENDU Trial

Ultimovacs ASA Announces First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer

Chief Executive Officer recently bought kr228k worth of stock

Ultimovacs Asa Announces Further Positive Topline Results from Phase I Uv1 Cancer Vaccine Combination Study in Metastatic Melanoma

Ultimovacs Announces First Patient Enrolled in Phase II Focus Trial of UV1 in Head-And-Neck Cancer

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation